ALEC
Alector, Inc.
ALEC offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over ALEC overall, supported by stronger fundamentals and lower modeled downside.
ALEC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Under pressure | |
| Strong |
ALEC's revenue, profitability and balance sheet are currently strong, but its cash flow is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALEC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 7x | $2.45 | — |
| Cheap | 17x | $6.09 | +149% |
| Fair | 19x | $6.80 | +178% |
| Expensive | 23x | $8.15 | +233% |
Historical ranges are pointers, not guarantees.
ALEC's PE is 7.0x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ALEC in the historical PE scenario, which offers more potential upside but is not a forecast.
ALEC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ALEC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ALEC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.35 | +$1.42 |
| Q2 2026 | -$1.10 | +$0.06 |
| Q1 2026 | -$1.19 | +$0.07 |
| Q4 2025 | -$1.39 | -$0.16 |
| Q3 2025 | -$1.07 | +$0.64 |
| Q2 2025 | -$1.16 | +$0.65 |
| Q1 2025 | -$1.26 | +$0.13 |
| Q4 2024 | -$1.23 | +$0.33 |
ALEC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ALEC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $162.9M | +4896% |
| Q2 2026 | $3.3M | -58% |
| Q1 2026 | $1M | -72% |
| Q4 2025 | $6.2M | -89% |
| Q3 2025 | $3.3M | -79% |
| Q2 2025 | $7.9M | -48% |
| Q1 2025 | $3.7M | -77% |
| Q4 2024 | $54.2M | +257% |
ALEC's revenue is growing: $163M last quarter, up 4896% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 76% | +1230 points |
| Q2 2026 | -735% | -301 points |
| Q1 2026 | -2382% | -1174 points |
| Q4 2025 | -634% | -621 points |
| Q3 2025 | -1154% | -838 points |
| Q2 2025 | -434% | -131 points |
| Q1 2025 | -1208% | -933 points |
| Q4 2024 | -13% | +299 points |
ALEC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ALEC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ALEC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.2M | +$8.4M |
| Q2 2026 | -$34.2M | +$14.8M |
| Q1 2026 | -$49.9M | +$10.9M |
| Q4 2025 | -$41.7M | +$13.5M |
| Q3 2025 | -$32.5M | +$18.4M |
| Q2 2025 | -$49.1M | +$14.1M |
| Q1 2025 | -$60.8M | +$1.1M |
| Q4 2024 | -$55.2M | -$8.9M |
ALEC has burned cash in almost every quarter: −$150M over the past year, against −$198M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ALEC on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALEC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +1.3M shares |
| 1 year | +9.6% | +9.9M shares |
| 3 years | +34% | +28.5M shares |
| 5 years | +32% | +27.2M shares |
| Available history | +50% | +37.7M shares |
ALEC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALEC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2022 | -4.1x | Net Cash |
ALEC has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ALEC on leverage, with a lower net debt burden relative to earnings.
ALEC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.0 | Neutral |
| Stochastic | 63.4 | Neutral |
ALEC's weekly RSI is 59 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALEC PE vs Healthcare Sector
| Metric | ALEC | Sector median | Relative |
|---|---|---|---|
| PE | 7x | 26x | 73% below |
ALEC has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ALEC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 19% above |
| 20 week MA | $1.98 | 24% above |
| 50 week MA | $1.97 | 24% above |
| 100 week MA | $1.86 | 32% above |
| 200 week MA | $3.98 | 38% below |
ALEC has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 38% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALEC on trend strength, trading above more of its moving averages.
ALEC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.6 | $15.3 | -13% |
| 2021 | $15.3 | $23.7 | +55% |
| 2022 | $23.7 | $8.84 | -63% |
| 2023 | $8.84 | $7.98 | -9.7% |
| 2024 | $7.98 | $1.78 | -78% |
| 2025 | $1.78 | $1.45 | -19% |
| 2026 YTD | $1.45 | $2.45 | +69% |
ALEC has finished four years in a row lower, and it's up 69% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALEC on returns for 2026, with the stronger performance.